Conference Coverage
ReachMD brings you the latest research, announcements, and conversations from the most important medical conferences around the world. Join us on the conference floor with keynote speakers, experts, and opinion leaders.
46-60 of 521
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Project Oncology®CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
Project Oncology®Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
Project Oncology®Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
Using fMRI to Identify Early Alzheimer’s Disease Subgroups
NeuroFrontiersUsing fMRI to Identify Early Alzheimer’s Disease Subgroups
Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
NeuroFrontiersEvaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Heart MattersRethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
- advertisement
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Heart MattersTargeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Heart MattersNavigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Project Oncology®Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Project Oncology®Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
- advertisement
Personalizing Treatment for gMG: On the Ground at AANEM
NeuroFrontiersPersonalizing Treatment for gMG: On the Ground at AANEM
Evaluating Sabirnetug in Early Alzheimer’s: Targeting Soluble Aβ Oligomers
NeuroFrontiersEvaluating Sabirnetug in Early Alzheimer’s: Targeting Soluble Aβ Oligomers
Individualized Cognitive Stimulation in Mild Alzheimer’s Disease: Evidence from a Multicenter RCT
NeuroFrontiersIndividualized Cognitive Stimulation in Mild Alzheimer’s Disease: Evidence from a Multicenter RCT
